Xenon Pharmaceuticals Inc. filings document a Nasdaq-listed Canadian biopharmaceutical issuer developing ion channel modulators for neurological and psychiatric disorders. Recent Form 8-K reports cover operating results, Regulation FD clinical disclosures, azetukalner study updates, investor presentation materials and exhibits tied to company press releases.
The filing record also includes proxy materials for shareholder voting and executive compensation, amendments to inducement equity incentive plans, registration and prospectus materials for common-share sales, pre-funded warrant and underwriting agreements, at-the-market offering disclosures, and capital-structure information for XENE common shares.
Morgan Stanley Wealth Management Canada Inc. filed a Form 144 notifying the sale of Common Shares tied to a Restricted share unit award vesting dated 03/12/2026 for 3,750 shares. The notice also lists a 03/10/2026 sale of 2,771 shares by Andrea DiFabio and a reported figure 166,559 appearing in the securities block.
XENE Rule 144 notice reporting proposed and recent transactions in Common Shares. The filing lists 3,750 Restricted Share Units vesting on 03/12/2026 and shows 2,607 Common Shares sold by Andrea DiFabio on 03/10/2026.
Ian Mortimer reported dispositions of Common Shares. The filing lists sales of 40,000 shares on 01/02/2026, 270,000 shares on 03/09/2026, and 11,269 shares on 03/10/2026. It also shows a 12,500 restricted share unit award vesting on 03/12/2026.
Xenon Pharmaceuticals Inc. outlined key details for its 2026 annual meeting of shareholders. The meeting is scheduled for June 2, 2026, with a record date for notice and voting of April 7, 2026, which is also the beneficial ownership determination date.
Holders of Xenon common shares are entitled to receive notice of and vote at the meeting. The company will not mail materials directly to non-objecting beneficial owners but will pay for distribution to objecting beneficial owners. Xenon is using notice-and-access for both registered and non-registered investors, and the related information was also submitted through a SEDAR+ filing furnished as Exhibit 99.1.
Xenon Pharmaceuticals Inc. completed a large equity financing, raising approximately $707.7 million in net proceeds from an underwritten public offering of common shares and pre-funded warrants. The company sold 12,236,843 common shares and pre-funded warrants to purchase 877,194 common shares, plus an additional 1,710,526 common shares after underwriters fully exercised their 30-day option.
The public offering price was $57.00 per common share and $56.9999 per pre-funded warrant, with underwriters purchasing at discounted prices. The pre-funded warrants have a $0.0001 exercise price, may be exercised for cash or on a cashless basis, and include a beneficial ownership cap initially set at 4.99%, adjustable by the holder up to 19.99% with advance notice. The warrants also provide protections and alternate consideration in certain major corporate transactions.
Xenon Pharmaceuticals Inc. reported that Chief Medical Officer Christopher John Kenney had performance share units (PSUs) granted on March 11, 2024 vest after the board determined milestone achievement. These PSUs, totaling 7,500 units, immediately converted into 7,500 common shares.
Following this vesting, Kenney sold 2,771 common shares on March 10, 2026 at an average price of $60.108 per share under a Rule 10b5-1 durable sell-to-cover instruction adopted on December 3, 2025 solely to satisfy tax withholding obligations related to the PSU vesting. After these transactions, he directly holds 4,729 common shares.
Xenon Pharmaceuticals Inc. Chief Legal Officer Andrea DiFabio reported equity compensation vesting and a related share sale. On March 9, 2026, 7,500 Performance Share Units vested based on the Board’s milestone assessment and were converted into 7,500 Common Shares at $0.00 per share.
On March 10, 2026, DiFabio sold 2,607 Common Shares in an open‑market transaction at an average price of $60.108 per share under a pre‑arranged Rule 10b5‑1 sell‑to‑cover instruction to satisfy tax withholding on the PSU vesting, leaving 4,893 Common Shares held directly.
Xenon Pharmaceuticals Inc. President & CEO Ian Mortimer reported a combination of option exercises, performance share vesting and share sales. He exercised stock options covering 290,000 Common Shares at exercise prices between $3.10 and $9.44 per share, and a 20,000-unit performance share award vested based on milestone achievement.
Across multiple open-market transactions, he sold a total of 281,269 Common Shares at weighted-average prices generally between the high-$50s and low-$60s. Footnotes state these sales were made under Rule 10b5‑1 trading arrangements, including a durable sell-to-cover instruction adopted solely to satisfy tax withholding on the vested performance share units. After these transactions, he holds 14,731 Common Shares directly and 14,300 Common Shares indirectly through his spouse.
Xenon Pharmaceuticals is offering 10,526,317 common shares and, in lieu of shares to certain investors, 877,194 pre-funded warrants via a prospectus supplement under its shelf registration. The offering price is $57.00 per common share (pre-funded warrant price $56.9999), with estimated net proceeds to the company of approximately $615.3 million and a possible additional 1,710,526 share option for the underwriters.
The prospectus supplement notes the pre-funded warrants have an exercise price of $0.0001, will not be listed, and holders will have limited liquidity until exercise. Shares outstanding used for dilution calculations were 80,010,790 common shares as of December 31, 2025. The underwriters expect delivery on or about March 12, 2026.